Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

Vaccine

Volumn 21, Issue 17-18, 2003, Pages 1995-2002

  Moorthy, V S ^a,c   McConkey, S ^a   Roberts, M ^a   Gothard, P ^a   Arulanantham, N ^a   Degano, P ^a   Schneider, J ^a   Hannan, C ^a   Roy, M ^b   Gilbert, S C ^a   Peto, T E A ^a   Hill, A V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Powderject Vaccines   (United States)

^c MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

Author keywords

Malaria; Safety; Vaccine

Indexed keywords

ANTIGEN; DNA VACCINE; EPITOPE; MALARIA VACCINE; PLASMID DNA; THROMBOSPONDIN RELATED ADHESION PROTEIN ANTIGEN; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ADULT; ARTICLE; BLISTER; BURNING SENSATION; CHEMICAL MODIFICATION; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERANCE; ERYTHEMA; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERPIGMENTATION; IMMUNITY; IMMUNIZATION; INGUINAL REGION; LETHARGY; LIVER; LYMPHADENOPATHY; MALAISE; MALARIA; MALE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEEDLE; NORMAL HUMAN; PAIN; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN EDEMA; SKIN INDURATION; SKIN TINGLING; VACCINATION; VACCINIA VIRUS; VACCINIA VIRUS ANKARA; VOLUNTEER;

EID: 0037449091     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00771-5     Document Type: Article

References (40)

1. World Health Organisation. Malaria Fact Sheet No. 94, 1996.
2. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A.et al. Direct gene transfer into mouse muscle in vivo. Science. 247:1990;1465-1468.
3. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J.et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
4. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y.et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 282:1998;476-480.
5. Wang R., Epstein J., Baraceros F.M., Gorak E.J., Charoenvit Y., Carucci D.J.et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10817-10822.
6. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M.et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:1998;397-402.
7. Hanke T., Samuel R.V., Blanchard T.J., Neumann V.C., Allen T.M., Boyson J.E.et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:1999;7524-7532.
8. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I.et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292:2001;69-74.
9. Sedegah M., Jones T.R., Kaur M., Hedstrom R., Hobart P., Tine J.A.et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. U.S.A. 95:1998;7648-7653.
10. McShane H., Brookes R., Gilbert S.C., Hill A.V. Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immunol. 69:2001;681-686.
11. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 408:2000;605-609.
12. Hanke T., Schneider J., Gilbert S.C., Hill A.V., McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine. 16:1998;426-435.
13. Mayr A., Stickl H., Muller H.K., Danner K., Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl). Zentralbl. Bakteriol. (B). 167:1978;375-390.
14. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U.S.A. 89:1992;10847-10851.
15. Ockenhouse C.F., Sun P.F., Lanar D.E., Wellde B.T., Hall B.T., Kester K.et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria (In Process Citation). J. Infect. Dis. 177:1998;1664-1673.
16. Gilbert S.C., Plebanski M., Harris S.J., Allsopp C.E., Thomas R., Layton G.T.et al. A protein particle vaccine containing multiple malaria epitopes. Nat. Biotechnol. 15:1997;1280-1284.
17. Robson K.J., Hall J.R., Jennings M.W., Harris T.J., Marsh K., Newbold C.I.et al. A highly conserved amino-acid sequence in thrombospondin. Nature. 335:1988;79-82.
18. Flanagan K.L., Plebanski M., Akinwunmi P., Lee E.A., Reece W.H., Robson K.J.et al. Broadly distributed T cell reactivity, with no immunodominant loci, to the pre-erythrocytic antigen thrombospondin-related adhesive protein of Plasmodium falciparum in West Africans. Eur. J. Immunol. 29:1999;1943-1954.
19. Wizel B., Houghten R., Church P., Tine J.A., Lanar D.E., Gordon D.M.et al. HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers. J. Immunol. 155:1995;766-775.
20. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1991;1031-1038.
21. Antoine G., Scheiflinger F., Dorner F., Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology. 244:1998;365-396.
22. Mackett M., Smith G.L., Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 49:1984;857-864.
23. Chakrabarti S., Brechling K., Moss B. Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5:1985;3403-3409.
24. Tacket C.O., Roy M.J., Widera G., Swain W.F., Broome S., Edelman R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine. 17:1999;2826-2829.
25. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., Robinson H.L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. U.S.A. 90:1993;11478-11482.
26. Han R., Reed C.A., Cladel N.M., Christensen N.D. Immunization of rabbits with cottontail rabbit papillomavirus E1 and E2 genes: protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection. Vaccine. 18:2000;2937-2944.
27. Mor G., Singla M., Steinberg A.D., Hoffman S.L., Okuda K., Klinman D.M. Do DNA vaccines induce autoimmune disease? Hum. Gene. Theor. 8:1997;293-300.
28. Ledwith B.J., Manam S., Troilo P.J., Barnum A.B., Pauley C.J., Griffiths T.G. IIet al. Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology. 43:2000;258-272.
29. Parker S.E., Borellini F., Wenk M.L., Hobart P., Hoffman S.L., Hedstrom R.et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum. Gene. Theor. 10:1999;741-758.
30. Hill A.V., Allsopp C.E., Kwiatkowski D., Anstey N.M., Twumasi P., Rowe P.A.et al. Common west African HLA antigens are associated with protection from severe malaria (see comments). Nature. 352:1991;595-600.
31. Hill A.V., Elvin J., Willis A.C., Aidoo M., Allsopp C.E., Gotch F.M.et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria (see comments). Nature. 360:1992;434-439.
32. Aidoo M., Lalvani A., Allsopp C.E., Plebanski M., Meisner S.J., Krausa P.et al. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet. 345:1995;1003-1007.
33. Clements-Mann M.L., Weinhold K., Matthews T.J., Graham B.S., Gorse G.J., Keefer M.C.et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J. Infect. Dis. 177:1998;1230-1246.
34. Pialoux G., Excler J.L., Riviere Y., Gonzalez-Canali G., Feuillie V., Coulaud P.et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res. Hum. Retroviruses. 11:1995;373-381.
35. Cadoz M., Strady A., Meignier B., Taylor J., Tartaglia J., Paoletti E.et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet. 339:1992;1429-1432.
36. Fries L.F., Tartaglia J., Taylor J., Kauffman E.K., Meignier B., Paoletti E.et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine. 14:1996;428-434.
37. Kanesa-thasan N., Smucny J.J., Hoke C.H., Marks D.H., Konishi E., Kurane I.et al. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine. 19:2000;483-491.
38. Mayr A. Historical review of smallpox, the eradication of smallpox and the attenuated smallpox MVA vaccine. Ber. Munch. Tierarztl. Wochenschr. 112:1999;322-328.
39. Stittelaar K.J., Kuiken T., de Swart R.L., van Amerongen G., Vos H.W., Niesters H.G.et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine. 19:2001;3700-3709.
40. Frey S.E., Couch R.B., Tacket C.O., Treanor J.J., Wolff M., Newman F.K.et al. National Institute of Allergy and Infectious Diseases Smallpox Vaccine Study Group. Clinical responses to undiluted and diluted smallpox vaccine. N. Engl. J. Med. 346:2002;1265-1274.